• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Opinion

Video

Benefits of Nonsteroidal Topical JAK Inhibitors for Moderate Pediatric Atopic Dermatitis

James Song, MD, FAAD, discusses how topical Janus kinase inhibitors offer distinct advantages for children with moderate atopic dermatitis by providing effective inflammation control without the adverse effects of topical corticosteroids, particularly in sensitive areas like the face and intertriginous regions.

Video Player is loading.
Current Time 0:00
Duration 1:55
Loaded: 0%
Stream Type LIVE
Remaining Time 1:55
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    This news content has been independently developed and is not endorsed by the American Academy of Dermatology.

    Video content above is prompted by the following:

    • For children with moderate disease who may not yet require systemic therapy (or who aren’t eligible), what advantages would a nonsteroidal, topical Janus kinase inhibitor offer over current options?

    Newsletter

    Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

    © 2025 MJH Life Sciences

    All rights reserved.